Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate

BACKGROUND: Etanercept (ETN) and adalimumab (ADA) are tumor necrosis factor inhibitors indicated for treatment of moderate to severe rheumatoid arthritis (RA) and are used as monotherapy or in combination with conventional disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX). Da...

Descripción completa

Detalles Bibliográficos
Autores principales: Tkacz, Joseph, Gharaibeh, Mahdi, DeYoung, Kathryn Henderson, Wilson, Kathleen, Collier, David, Oko-osi, Hafiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391042/
https://www.ncbi.nlm.nih.gov/pubmed/32105179
http://dx.doi.org/10.18553/jmcp.2020.26.3.285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391042/
https://www.ncbi.nlm.nih.gov/pubmed/32105179
http://dx.doi.org/10.18553/jmcp.2020.26.3.285

Ejemplares similares